Phase 1 Clinical Trial MPC-2130 Treatment of Blood Cancers / Refractory Cancer
Phase 1
Terminated
- Conditions
- Cancer
- First Posted Date
- 2006-10-12
- Last Posted Date
- 2009-11-03
- Lead Sponsor
- Myriad Therapeutics, Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT00387153
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath